|drug1396||Group B Control Wiki||1.00|
|drug2197||Nitazoxanide with ivermectin Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because it impairs lysosomal function and reorganizes lipid raft (cholesterol and sphingolipid rich microdomains in the plasma membrane) content in cells, which are both critical determinants of Emerging Viral Disease (EVD) infection. This hypothesis is based on a growing literature linking chloroquine to antiviral activity. It is estimated that enough information exists to launch a clinical trial of hydroxychloroquine for COVID-19.
Description: Rate of hospitalizationMeasure: Sub Study 1: Patients Time: 21 days
Description: Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 monthsMeasure: Sub Study 2: Health Care Workers Time: 2 months
Description: any house hold member who has reported symptoms or test positive for COVID 19 during their 14 day active participationMeasure: Sub Study 1: Patients: Rate of secondary infection of co-inhabitants Time: 14 days after enrollment of the household
Description: Assessment of any medical events that occur during the 14 day active period that is felt to be related to receipt of HCQMeasure: Sub Study 1: Patients: Adverse Events Time: 14 day active period
Description: If a test comes back negative, participant would be notified as such and told to destroy their pills as they are withdrawnMeasure: Sub Study 1: Patients: Negative for COVID-19 Time: up to 5 days after enrolling
Description: Any work time missed because the participant experienced COVID-like symptoms during their active 2 month periodMeasure: Sub Study 2:Health Care Workers:Number of shifts missed Time: up to ~60 days after enrollment
Description: Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQMeasure: Sub Study 2:Health Care Workers:Rate of adverse events Time: up to ~60 days after enrollment
Description: if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month periodMeasure: Sub Study 2:Health Care Workers:Rate of hospitalization Time: up to ~60 days after enrollment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports